News | July 06, 2024
Dabur India updates on Q1 FY25
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Dyslipidemia is a critical risk factor for cardiovascular diseases
Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
_256_384.jpg)
This facility manufactures APIs & formulations of oncology and non-oncology products.
The company plans to add 1700 beds by FY27 through the organic route
International Business is expected to register double-digit growth in constant currency terms
Subscribe To Our Newsletter & Stay Updated
